Ausgabe 5/2020
Inhalt (19 Artikel)
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
Csaba Kerepesi, Tibor Bakacs, Ralph W. Moss, Shimon Slavin, Colin C. Anderson
Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density
Akinori Nukui, Takao Kamai, Kyoko Arai, Toshiki Kijima, Minoru Kobayashi, Takahiro Narimatsu, Tsunehito Kambara, Hideo Yuki, Hironori Betsunoh, Hideyuki Abe, Yoshitatsu Fukabori, Masahiro Yashi, Ken-Ichiro Yoshida
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients
Pierre Rosenbaum, Cécile Artaud, Sylvie Bay, Christelle Ganneau, Mario Campone, Suzette Delaloge, Carole Gourmelon, Delphine Loirat, Jacques Medioni, François Pein, Marie-Paule Sablin, Olivier Tredan, Andrea Varga, Claude Leclerc
Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
Henna Kasanen, Micaela Hernberg, Siru Mäkelä, Oscar Brück, Susanna Juteau, Laura Kohtamäki, Mette Ilander, Satu Mustjoki, Anna Kreutzman
Nonlinear response to cancer nanotherapy due to macrophage interactions revealed by mathematical modeling and evaluated in a murine model via CRISPR-modulated macrophage polarization
Fransisca Leonard, Louis T. Curtis, Ahmed R. Hamed, Carolyn Zhang, Eric Chau, Devon Sieving, Biana Godin, Hermann B. Frieboes
Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes
Kenichiro Yahiro, Yoshihiro Matsumoto, Hisakata Yamada, Makoto Endo, Nokitaka Setsu, Toshifumi Fujiwara, Makoto Nakagawa, Atsushi Kimura, Eijiro Shimada, Seiji Okada, Yoshinao Oda, Yasuharu Nakashima
Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
Anne Fröhlich, Dennis Niebel, Simon Fietz, Eva Egger, Andrea Buchner, Judith Sirokay, Jennifer Landsberg
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
Daan P. Hurkmans, Merian E. Kuipers, Jasper Smit, Ronald van Marion, Ron H. J. Mathijssen, Piet E. Postmus, Pieter S. Hiemstra, Joachim G. J. V. Aerts, Jan H. von der Thüsen, Sjoerd H. van der Burg
Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation
Fei-fei Gu, Jing-jing Wu, Yang-yang Liu, Yue Hu, Jin-yan Liang, Kai Zhang, Ming Li, Yan Wang, Yong-an Zhang, Li Liu
CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer
Songyang Liu, Wei Zhang, Kai Liu, Yingchao Wang
Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers
Julia Y. Tsang, Chun-Sing Ho, Yun-Bi Ni, Yan Shao, Ivan K. Poon, Siu-Ki Chan, Sai-Yin Cheung, Ka-Ho Shea, Monalyn Marabi, Gary M. Tse
Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia
Denise Risnik, Ana Colado, Enrique Podaza, María Belén Almejún, Esteban Enrique Elías, Raimundo Fernando Bezares, Horacio Fernández-Grecco, Noé Seija, Pablo Oppezzo, Mercedes Borge, Romina Gamberale, Mirta Giordano
CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma
Qiu-Zhong Pan, Qing Liu, Yu-Qing Zhou, Jing-Jing Zhao, Qi-Jing Wang, Yong-Qiang Li, Yan Tang, Jia-Mei Gu, Jia He, Shi-Ping Chen, De-Sheng Weng, Jian-Chuan Xia
LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development
Lining Zhou, Yu Tian, Fang Guo, Bin Yu, Jiali Li, Huaxi Xu, Zhaoliang Su
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
Masanori Noguchi, Gaku Arai, Shin Egawa, Chikara Ohyama, Seiji Naito, Kazumasa Matsumoto, Hirotsugu Uemura, Masayuki Nakagawa, Yasutomo Nasu, Masatoshi Eto, Shigetaka Suekane, Tetsuro Sasada, Shigeki Shichijo, Akira Yamada, Tatsuyuki Kakuma, Kyogo Itoh
Long-term surviving cancer patients as a source of therapeutic TCR
Else Marit Inderberg, Sébastien Wälchli
New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia
Stephanie Jordaens, Leah Cooksey, Laurie Freire Boullosa, Viggo Van Tendeloo, Evelien Smits, Ken I. Mills, Kim H. Orchard, Barbara-ann Guinn
Current progress in NK cell biology and NK cell-based cancer immunotherapy
Raquel Tarazona, Nelson Lopez-Sejas, Beatriz Guerrero, Fakhri Hassouneh, Isabel Valhondo, Alejandra Pera, Beatriz Sanchez-Correa, Nieves Pastor, Esther Duran, Corona Alonso, Rafael Solana
“Tumor immunology meets oncology (TIMO) XV”, April 25th–27th 2019, Halle/Saale, Germany
André Steven, Chiara Massa, Barbara Seliger